Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Catalyst Pharma (CPRX)
NASDAQ:CPRX
Holding CPRX?
Track your performance easily
CPRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.00 - $24.27
Previous Close$21.12
Volume863.88K
Average Volume (3M)945.28K
Market Cap
$2.52B
Enterprise Value$2.08B
Total Cash (Recent Filing)$442.33M
Total Debt (Recent Filing)$2.89M
Price to Earnings (P/E)18.0
Beta1.10
Next Earnings
Mar 12, 2025EPS Estimate
$0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.17
Shares Outstanding119,273,436
10 Day Avg. Volume1,359,944
30 Day Avg. Volume945,281
Standard Deviation0.14
R-Squared0.08
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)3.82
Price to Sales (P/S)5.54
Price to Cash Flow (P/CF)8.80
P/FCF Ratio8.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.52
Enterprise Value/Gross Profit6.01
Enterprise Value/Ebitda9.02
Forecast
1Y Price Target
$32.20Price Target Upside49.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Catalyst Pharma News
PremiumCompany Announcements
Catalyst Pharmaceuticals Reports Strong Q3 2024 Earnings
Ownership Overview
5.98% Insiders
17.90% Mutual Funds
18.93% Other Institutional Investors
30.44% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CPRX FAQ
What was Catalyst Pharma’s price range in the past 12 months?
Catalyst Pharma lowest stock price was $13.00 and its highest was $24.27 in the past 12 months.
What is Catalyst Pharma’s market cap?
Currently, no data Available
When is Catalyst Pharma’s upcoming earnings report date?
Catalyst Pharma’s upcoming earnings report date is Mar 12, 2025 which is in 109 days.
How were Catalyst Pharma’s earnings last quarter?
Catalyst Pharma released its earnings results on Nov 06, 2024. The company reported $0.35 earnings per share for the quarter, beating the consensus estimate of $0.304 by $0.046.
Is Catalyst Pharma overvalued?
According to Wall Street analysts Catalyst Pharma’s price is currently Undervalued.
Does Catalyst Pharma pay dividends?
Catalyst Pharma does not currently pay dividends.
What is Catalyst Pharma’s EPS estimate?
Catalyst Pharma’s EPS estimate is $0.34.
How many shares outstanding does Catalyst Pharma have?
Catalyst Pharma has 119,273,440 shares outstanding.
What happened to Catalyst Pharma’s price movement after its last earnings report?
Catalyst Pharma reported an EPS of $0.35 in its last earnings report, beating expectations of $0.304. Following the earnings report the stock price went up 2.378%.
Which hedge fund is a major shareholder of Catalyst Pharma?
Among the largest hedge funds holding Catalyst Pharma’s share is Deerfield Management Company, LP. It holds Catalyst Pharma’s shares valued at 124M.
---
Catalyst Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.20 (49.91% Upside)
$32.20 (49.91% Upside)
Blogger Sentiment
Bullish
CPRX Sentiment 87%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 3.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 10.4%
Last 30 Days ▲ 10.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.71%
12-Months-Change
Fundamentals
Return on Equity
28.29%
Trailing 12-Months
Asset Growth
86.83%
Trailing 12-Months
Company Description
Catalyst Pharma
Catalyst Pharmaceuticals is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasmsThe company was founded Huckel E. Hubert in January 2002 and is headquartered in Coral Gables, FL.
---
CPRX Earnings Call
Q3 2024
0:00 / 0:00
---
CPRX Stock 12 Month Forecast
Average Price Target
$32.20
▲(49.91% Upside)
Technical Analysis
Axsome Therapeutics
―
PTC Therapeutics
―
Eagle Pharmaceuticals
―
ACADIA Pharmaceuticals
―
Best Analysts Covering CPRX
1 Year
1 Year Success Rate
16/19 ratings generated profit
1 Year Average Return
+32.36%
reiterated a buy rating 9 months ago
Copying Charles Duncan's trades and holding each position for 1 Year would result in 84.21% of your transactions generating a profit, with an average return of +32.36% per trade.
---